Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05946772

Cyclosporine In Takotsubo Syndrome

Led by University Hospital Heidelberg · Updated on 2026-05-01

204

Participants Needed

24

Research Sites

156 weeks

Total Duration

On this page

Sponsors

U

University Hospital Heidelberg

Lead Sponsor

G

German Centre of Cardiovascular Research (DZHK)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to investigate the impact of repetitive acute Cyclosporine A (CsA) bolus therapy in patients suffering from TTS with an elevated risk of impaired outcome. The main question it aims to answer is whether CsA reduces myocardial injury (primary outcome). Participants will receive CsA or placebo at baseline and every 12h in the first 24h after study inclusion. Researchers will compare CsA and the placebo group to see if a) myocardial injury is reduced, and b) ejection fraction is improved compared to baseline, as well as several other secondary endpoints over a one year follow-up.

CONDITIONS

Official Title

Cyclosporine In Takotsubo Syndrome

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged over 18
  • Enrollment and first investigational medicinal product administration within 24 hours after cardiac catheterization
  • Regional Wall Motion Abnormality consistent with Takotsubo syndrome in angiography or echocardiography
  • InterTAK prognostic score or GEIST Score of 9 or higher
  • Written informed consent
Not Eligible

You will not qualify if you...

  • Acute coronary syndrome with significant coronary stenosis or percutaneous coronary intervention
  • Infection with positive blood culture at the time of study inclusion
  • History of hypersensitivity to cyclosporine
  • History of hypersensitivity to egg, peanut, or soybean proteins
  • History of chronic renal insufficiency (creatinine clearance less than 30 ml/min/1.73m² or severe renal insufficiency treatment)
  • History of liver insufficiency
  • Uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg) at screening
  • Current medication with Hypericum perforatum, Stiripentol, Aliskiren, Bosentan, or Rosuvastatin over 5 mg within 48 hours before treatment
  • Female patients currently pregnant or women of childbearing age without negative pregnancy test or effective contraception
  • Any disorder causing immunological dysfunction within 6 months prior to presentation
  • Immunosuppressive, chemotherapy, or antibody treatment
  • Participation in other clinical trials except non-interventional trials

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 24 locations

1

Kerckhoff Heart Center, Bad Nauheim / Gießen University

Bad Nauheim, Germany

Actively Recruiting

2

Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin

Berlin, Germany

Actively Recruiting

3

Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

Berlin, Germany

Actively Recruiting

4

Heart Centre - University Hospital Bonn

Bonn, Germany

Actively Recruiting

5

Department of Cardiology, University Hospital Köln

Cologne, Germany

Actively Recruiting

6

Department of Cardiology, University Hospital Dresden

Dresden, Germany

Actively Recruiting

7

Cardiovascular Centre - University Hospital Düsseldorf

Düsseldorf, Germany

Actively Recruiting

8

Department of Cardiology - University Hospital Essen

Essen, Germany

Actively Recruiting

9

Department of Cardiology, University Hospital Frankfurt

Frankfurt, Germany

Actively Recruiting

10

University Medical Center Göttingen

Göttingen, Germany

Actively Recruiting

11

Department of Cardiology, University Hospital Halle

Halle, Germany

Actively Recruiting

12

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

Actively Recruiting

13

Department of Cardiology, Heidelberg University Hospital

Heidelberg, Germany, 69120

Actively Recruiting

14

Department of Cardiology, University Hospital Leipzig

Leipzig, Germany

Actively Recruiting

15

Leipzig Heart Center

Leipzig, Germany

Actively Recruiting

16

University Medical Center Schleswig-Holstein/Campus Lübeck

Lübeck, Germany

Actively Recruiting

17

Department of Cardiology, University Hospital Magdeburg

Magdeburg, Germany

Actively Recruiting

18

Department of Cardiology, University Hospital Mainz

Mainz, Germany

Actively Recruiting

19

Department of Cardiology, University Hospital Mannheim

Mannheim, Germany

Actively Recruiting

20

Department of Cardiology, Hospital of the Ludwig-Maximilians-University Munich

München, Germany

Actively Recruiting

21

University Hospital rechts der Isar, Technical University of Munich

München, Germany

Actively Recruiting

22

Department of Cardiology, University Hospital Rostock

Rostock, Germany

Actively Recruiting

23

Department of Cardiology, University Hospital Ulm

Ulm, Germany

Actively Recruiting

24

Department of Cardiology, University Hospital Wuppertal

Wuppertal, Germany

Actively Recruiting

Loading map...

Research Team

B

Bastian Bruns, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here